Author:
Abdukadir Azhar,Rabeh Nadia,Aljoudi Sara,Dimassi Zakia,Alhosani Khalood Mohamed,Hamdan Hamdan
Publisher
Springer Nature Singapore
Reference38 articles.
1. Barnett M, Wang D, Beadnall H, Bischof A, Brunacci D, Butzkueven H, Brown JWL, Cabezas M, Das T, Dugal T, Guilfoyle D, Klistorner A, Krieger S, Kyle K, Ly L, Masters L, Shieh A, Tang Z, van der Walt A, Wang C (2023) A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis. NPJ Dig Med 6(1):196. https://doi.org/10.1038/s41746-023-00940-6
2. Barr H, Given K, Mcclain C, Gruber R, Ofengeim D, Macklin W, Hughes E (2020, December). BTK signaling regulates real-time microglial dynamics and prevents demyelination in a novel in vivo model of antibodymediated cortical demyelination. In MULTIPLE SCLEROSIS JOURNAL (Vol. 26, No. 3_ SUPPL, pp. 39-39). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD
3. Bomprezzi R (2015) Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview. Ther Adv Neurol Disord 8(1):20–30. https://doi.org/10.1177/1756285614564152
4. Brandstadter R, Katz Sand I (2017) The use of natalizumab for multiple sclerosis. Neuropsychiatr Dis Treat 13:1691–1702
5. Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, Fagius J, Rose J, Nelson F, Barreira AA, Carlson K, Han X, Moraes D, Morgan A, Quigley K, Yaung K, Buckley R, Alldredge C, Clendenan A, Helenowski IB (2019) Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA 321(2):165–174. https://doi.org/10.1001/jama.2018.18743